HIF-1α和VEGF-C在前列腺癌中的表达及意义  

Expression and Clinical Significance of HIF-1α and VEGF-C in Prostate Cancer

作　　者：王晋龙[1] 白铁男[1] 胡海龙[1] 韩瑞发[2] 赵朋[1] 

机构地区：[1]天津医科大学第二医院泌尿外科,300221 [2]天津市泌尿外科研究所

出　　处：《天津医药》2012年第1期4-6,98,共4页Tianjin Medical Journal

基　　金：天津市应用基础及前沿技术研究计划(项目编号:09JCYBJC27800);天津市卫生局科技基金(项目编号:09KZ90)

摘　　要：目的:探讨缺氧诱导因子(HIF)-1α和血管内皮生长因子(VEGF)-C在前列腺癌中的表达及其临床意义。方法:应用免疫组织化学SABC法检测59例前列腺癌(PC)组织及13例良性前列腺增生(BPH)组织中HIF-1α和VEGF-C表达情况,分析两者相关性及其表达与临床病理特征的关系。结果:HIF-1α和VEGF-C在PC组中的阳性表达率分别为66.1%和76.3%,明显高于BPH组(7.7%和0),差异有统计学意义(P<0.01)。HIF-1α和VEGF-C阳性表达率在不同Gleason评分、TNM分期和有无淋巴结转移的患者间差异有统计学意义(P<0.05或P<0.01),而不同年龄和前列腺特异性抗原(PSA)患者间差异无统计学意义(P>0.05)。在PC中HIF-1α与VEGF-C的表达呈正相关(rs=0.261,P<0.05)。结论:HIF-1α的过表达可能通过激活下游基因VEGF-C的表达协同参与前列腺癌的发生、发展,促进肿瘤的转移。Objective：To study the expression and clinical significance of hypoxia-inducible factor 1α（HIF-1α） and vascular endothelial growth factor C（VEGF-C） in the prostate carcinoma（PC）.Methods：The expression levels of HIF-1α and VEGF-C were detected by SABC immunohistochemical analysis in 59 cases of PC and 13 cases of benign prostatic hyperplasia（BPH）.The expression and relationship of HIF-1α and VEGF-C with clinic-pathological features were analyzed.Results：The positive expression rates of HIF-1α and VEGF-C were significantly higher in PC（66.1% and 76.3% respectively） compared with those of BPH（7.7% and 0 respectively,P 0.01）.There were significant differences in positive expression rates of HIF-1α and VEGF-C between the tumor differentiation,clinical stages and lymph node metastasis（P 0.05 or P 0.01）,but no significant correlation between positive expression rates of HIF-1α and VEGF-C,patient-age and prostate specific antigen（PSA） level（P 0.05）.There was a positive correlation between the expressions of HIF-1α and VEGF-C in prostatic carcinoma（rs = 0.261,P 0.05）.Conclusion：The over-expression of HIF-1α induced tumor invasion by activating the transcription of VEGF-C,which may play a great role in the genesis and development of prostate tumor.

关 键 词：缺氧诱导因子1 Α亚基 血管内皮生长因子C 前列腺肿瘤 癌 前列腺增生 

分 类 号：R737.9[医药卫生—肿瘤]